Bryan Zimdahl

Bryan Zimdahl has over 15 years of experience in the field of clinical science and regulatory affairs. Bryan began their career in 2005 as an Undergraduate Research Fellow at Villanova University, where they were mentored by Dr. Mary Kay Francis, Ph.D. In 2006, they were a Howard Hughes Summer Research Fellow at Princeton University, mentored by Dr. Yibin Kang, Ph.D. In 2013, they were a Visiting Graduate Scholar/Post-doc Research Fellow at the University of California, San Diego, mentored by Dr. Tannishtha Reya, Ph.D. In 2014, they were a Postdoctoral Research Fellow at Stanford University School of Medicine, mentored by Dr. Philip Beachy, Ph.D. In 2015, they joined Eureka Therapeutics, Inc. as Director of Clinical Science and Regulatory Affairs. In this role, they led the development of clinical study protocols, Investigator’s Brochures (IB), informed consent forms (ICF), clinical study reports, and other key clinical documents. Bryan also contributed to clinical data analysis, interpretation, and summarizing study results for clinical trials, including working closely with study medical monitors to review patient safety data. Bryan also managed the preparation, submission, and maintenance of all regulatory applications (INDs, etc.). Bryan has also held positions as Associate Director of Clinical Sciences, Clinical Scientist III, and Clinical Scientist II, and Research/Clinical Scientist in Preclinical Development.

Bryan Zimdahl completed a Bachelor of Science in Biology with a Minor in Chemistry from Villanova University between 2003 and 2007. Bryan then went on to pursue a Doctor of Philosophy in Molecular Cancer Biology and Cell and Molecular Biology from Duke University from 2007 to 2013. Following this, they were a Post-doctoral fellow in Stem Cell Biology and Cancer Biology at Stanford University School of Medicine. In 2017, they completed a Postgraduate Course in Clinical Pharmacology, Drug Development, and Regulation at Tufts University School of Medicine.